Spots Global Cancer Trial Database for A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
Official Title: A Phase 1 Clinical Study of Nemtabrutinib (MK-1026) in Japanese Participants With Hematological Malignancies (BELLWAVE-002)
Study ID: NCT05673460
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of nemtabrutinib in Japanese participants with mature B-cell neoplasms.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nagoya University Hospital ( Site 0003), Nagoya, Aichi, Japan
National Cancer Center Hospital East ( Site 0002), Kashiwa, Chiba, Japan
Kindai University Hospital ( Site 0006), Osakasayama, Osaka, Japan
Chiba Cancer Center ( Site 0005), Chiba, , Japan
Kyushu University Hospital ( Site 0008), Fukuoka, , Japan
Okayama University Hospital ( Site 0007), Okayama, , Japan
Yamagata University Hospital ( Site 0001), Yamagata, , Japan
Contact Details
Name: Medical Director
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
